Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor

$ 14.50

4.7
(656)
In stock
Description

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Great Strides in Precision Medicine: Personalized Oncology

Lapatinib and lapatinib plus trastuzumab therapy versus

Lapatinib and lapatinib plus trastuzumab therapy versus

Page 1526 – Cancer Therapy Advisor

Molecules, Free Full-Text

January 2011 - Oncology Practice Digital Network

Risk-based decision-making in the treatment of HER2-positive early

A Phase 1B open-label study of gedatolisib (PF-05212384) in

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies

Page 1597 – Cancer Therapy Advisor

Pharmaceuticals, Free Full-Text